Publications by authors named "Niloufar Haddadi"
Article Synopsis
- NAFLD is the most common liver disease globally and linked to high cardiovascular risk, with no FDA-approved treatments available.
- Researchers conducted a 3-month trial with 150 NAFLD patients testing metformin, silymarin, pioglitazone, and vitamin E against a placebo.
- Results showed improvements in waist circumference and BMI across all groups, and notable decreases in liver enzymes for silymarin, pioglitazone, and vitamin E, indicating their potential benefits without significant side effects.